The Fungal Gut Microbiome Exhibits Reduced Diversity and Increased Relative Abundance of Ascomycota in Severe COVID-19 Illness and Distinct Interconnected Communities in SARS-CoV-2 Positive Patients.
COVID-19
SARS-CoV-2
co-occurrence network
intestinal microbiota
mycobiome
severity
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
01
2022
accepted:
25
03
2022
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
Clinical and experimental studies indicate that the bacterial and fungal gut microbiota modulates immune responses in distant organs including the lungs. Immune dysregulation is associated with severe SARS-CoV-2 infection, and several groups have observed gut bacterial dysbiosis in SARS-CoV-2 infected patients, while the fungal gut microbiota remains poorly defined in these patients. We analyzed the fungal gut microbiome from rectal swabs taken prior to anti-infective treatment in 30 SARS-CoV-2 positive (21 non-severe COVID-19 and 9 developing severe/critical COVID-19 patients) and 23 SARS-CoV-2 negative patients by ITS2-sequencing. Pronounced but distinct interconnected fungal communities distinguished SARS-CoV-2 positive and negative patients. Fungal gut microbiota in severe/critical COVID-19 illness was characterized by a reduced diversity, richness and evenness and by an increase of the relative abundance of the Ascomycota phylum compared with non-severe COVID-19 illness. A dominance of a single fungal species with a relative abundance of >75% was a frequent feature in severe/critical COVID-19. The dominating fungal species were highly variable between patients even within the groups. Several fungal taxa were depleted in patients with severe/critical COVID-19.The distinct compositional changes of the fungal gut microbiome in SARS-CoV-2 infection, especially in severe COVID-19 illness, illuminate the necessity of a broader approach to investigate whether the differences in the fungal gut microbiome are consequences of SARS-CoV-2 infection or a predisposing factor for critical illness.
Identifiants
pubmed: 35521219
doi: 10.3389/fcimb.2022.848650
pmc: PMC9062042
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
848650Informations de copyright
Copyright © 2022 Reinold, Farahpour, Schoerding, Fehring, Dolff, Konik, Korth, van Baal, Buer, Witzke, Westendorf and Kehrmann.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2018 Jun 28;131(26):2978-2986
pubmed: 29674425
Microbiome. 2017 Nov 25;5(1):153
pubmed: 29178920
Eur J Gastroenterol Hepatol. 2003 Jun;15(6):697-8
pubmed: 12840682
Cell Host Microbe. 2017 Dec 13;22(6):809-816.e4
pubmed: 29174402
Gastroenterology. 2020 Oct;159(4):1302-1310.e5
pubmed: 32598884
Int J Food Microbiol. 2016 Apr 2;222:23-9
pubmed: 26828815
Genome Biol. 2020 Apr 28;21(1):99
pubmed: 32345342
Gastroenterology. 2015 Jan;148(1):30-6
pubmed: 25447847
J Clin Gastroenterol. 2014 Jul;48(6):513-23
pubmed: 24275714
Front Microbiol. 2018 Aug 14;9:1868
pubmed: 30154775
PLoS One. 2021 Oct 5;16(10):e0258271
pubmed: 34610041
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Cell. 2019 Mar 7;176(6):1340-1355.e15
pubmed: 30799037
Nat Rev Gastroenterol Hepatol. 2009 May;6(5):306-14
pubmed: 19404271
BMJ. 2020 Sep 4;370:m3379
pubmed: 32887691
Sci Rep. 2019 Jan 24;9(1):742
pubmed: 30679586
mSphere. 2018 Mar 28;3(2):
pubmed: 29600282
Cell Host Microbe. 2019 Mar 13;25(3):404-417.e6
pubmed: 30870622
J Antibiot (Tokyo). 1991 Sep;44(9):919-24
pubmed: 1938613
Science. 2021 Mar 12;371(6534):1154-1159
pubmed: 33707263
Inflamm Bowel Dis. 2015 Aug;21(8):1948-56
pubmed: 26083617
Engineering (Beijing). 2020 Oct;6(10):1178-1184
pubmed: 33520333
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
Gut. 2000 Sep;47(3):397-403
pubmed: 10940278
Curr Opin Microbiol. 2020 Aug;56:67-73
pubmed: 32679448
Nat Commun. 2020 May 22;11(1):2577
pubmed: 32444671
BMC Bioinformatics. 2016 Apr 26;17(1):185
pubmed: 27112575
Microorganisms. 2018 Mar 09;6(1):
pubmed: 29522426
Med Mycol. 2007 Dec;45(8):691-700
pubmed: 17885943
Toxins (Basel). 2014 Jan 28;6(2):430-52
pubmed: 24476707
J Virol. 2020 Jul 30;94(16):
pubmed: 32461320
J Infect Dis. 2019 Jan 9;219(3):497-508
pubmed: 30202890
Curr Opin Microbiol. 2020 Dec;58:116-123
pubmed: 33120172
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
Am J Respir Crit Care Med. 2021 Feb 1;203(3):307-317
pubmed: 33480831
Front Microbiol. 2021 Jul 19;12:705020
pubmed: 34349747
Clin Infect Dis. 2020 Dec 17;71(10):2669-2678
pubmed: 32497191
Cytokine Growth Factor Rev. 2021 Apr;58:82-91
pubmed: 33573850
Gut. 2021 Apr;70(4):698-706
pubmed: 33431578
Gut. 2021 Feb;70(2):276-284
pubmed: 32690600
Pathogens. 2019 May 21;8(2):
pubmed: 31117285
Front Microbiol. 2016 Aug 03;7:1227
pubmed: 27536299
J Physiol. 1998 Mar 15;507 ( Pt 3):819-30
pubmed: 9508842
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):
pubmed: 33526674
J Fungi (Basel). 2020 Nov 01;6(4):
pubmed: 33139651
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):331-345
pubmed: 30824884
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Commun Biol. 2021 Apr 13;4(1):480
pubmed: 33850296
Front Cell Infect Microbiol. 2021 Nov 17;11:747816
pubmed: 34869058